300723.SZ Overview

Company Profile

ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale and retail trade; information technology; and technology promotion and application services. The company was formerly known as ApicHope Pharmaceutical Co., Ltd and changed its name to ApicHope Pharmaceutical Group Co., Ltd. in December 2024. ApicHope Pharmaceutical Group Co., Ltd. was founded in 2002 and is headquartered in Guangzhou, China.

Related stocks

300601.SZ

300601.SZ • China

KANGTAI BIOLOGICAL

13.44 CNY

2.25B USD 1Y -20.6%

000766.SZ

000766.SZ • China

TONGHUA GOLDEN HORSE

14.97 CNY

2.16B USD 1Y -40.1%

688131.SS

688131.SS • China

SHANGHAI HAOYUAN CHEMEXPRESS CO

93.16 CNY

2.97B USD 1Y +9%

300199.SZ

300199.SZ • China

23.71 CNY

3.13B USD 1Y +8.6%

300725.SZ

300725.SZ • China

51.01 CNY

1.78B USD 1Y +22.3%

600518.SS

600518.SS • China

KANGMEI PHARMACEUTICAL CO LTD

1.35 CNY

2.79B USD 1Y -33.8%

300363.SZ

300363.SZ • China

23.68 CNY

1.93B USD 1Y -9.3%

688321.SS

688321.SS • China

SHENZHEN CHIPSCREEN BIOSCIENCES

24.31 CNY

1.61B USD 1Y -23.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Drug Manufacturers - Specialty & Generic

Website

https://www.apichope.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

58.8% p.a.

Max Drawdown (5Y)

-63.3%

Sharpe Ratio (5Y)

0.14

Beta Factor

0.75

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

🔴 High valuation risk: Avg P/E of 66.8 (Elevated multiple compression risk)

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Elevated Short-Term Volatility: 3Y volatility (66.8%) is noticeably higher than the 5Y average (58.8%).

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (58.8% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -63.3% in the extended horizon.